Litcius/Paper detail

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

Andrea B. Apolo, Rosa Nadal, Yusuke Tomita, Nicole N. Davarpanah, Lisa M. Cordes, Seth M. Steinberg, Liang Cao, Howard L. Parnes, Rene Costello, Maria J. Merino, Les Folio, Liza Lindenberg, Mark Raffeld, Jeffrey Lin, Min-Jung Lee, Sunmin Lee, Sylvia V. Alarcon, Akira Yuno, Nancy A. Dawson, Kimaada Allette, Arpita Singha Roy, Dinuka De Silva, Molly M. Lee, Tristan M. Sissung, William D. Figg, Piyush K. Agarwal, John J Wright, Yang‐Min Ning, James L. Gulley, William L. Dahut, Donald P. Bottaro, Jane B. Trepel

2020The Lancet Oncology89 citationsDOIOpen Access PDF

Topics & Concepts

CabozantinibMetastatic Urothelial CarcinomaMedicineResponse Evaluation Criteria in Solid TumorsOncologyInternal medicineCohortClinical endpointRefractory (planetary science)Progressive diseaseCancerUrologyChemotherapyClinical trialBladder cancerUrothelial carcinomaPhysicsAstrobiologyBladder and Urothelial Cancer TreatmentsPhagocytosis and Immune RegulationCancer Immunotherapy and Biomarkers